TIL
Instil Bio, Inc.
1 day chart
About TIL
Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL), therapies for the treatment of patients with cancer. The Company's lead TIL product candidate is ITIL-168, for the treatment of advanced melanoma. ITIL-168, is an autologous TIL therapy that is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. It is also developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. Its lead CoStAR-TIL product candidate is ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (FOLR1) a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, non-small cell lung cancer (NSCLC) and renal cancer.
Buy US stocks in Australia with $0 brokerage and trade TIL today!
$656.25M
-
0.00%
84.3K
$5.17
$4.96
$5.01
$23.22
$3.90
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.